Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Allergan’s wholly-owned subsidiary, Allergan Sales LLC agreed to acquire Keller Medical, Inc., a privately held medical device company and developer of the Keller Funnel®. The Keller Funnel is a cone-shaped, lubricated plastic funnel that reduces surgeon and patient contact during breast augmentation or reconstruction procedures. Keller Medical launched the original Keller Funnel® in 2009 and the Keller Funnel® 2 in 2014, and hundreds of thousands of funnels have been used in breast augmentation or reconstruction procedures to date globally.
“Allergan is focused on providing technologies and products to help our surgeon customers improve procedures and Keller Funnel is that product for breast augmentation and reconstruction procedures,” said David Moatazedi, Senior Vice President of Medical Aesthetics at Allergan. “The Keller Funnel was developed and designed by pioneering surgeons to improve breast implantation, and reduce the risks of implant contamination during procedures. This is a natural complement to our world-class plastic surgery and regenerative medicine business, and marketing this innovative device further enhances our commitment to our customers and patients.”
The Keller Funnel is used to assist plastic surgeons in breast augmentation and reconstruction procedures by guiding silicone gel implants into the surgical pocket. The Funnel also allows surgeons to use a “no-touch” technique, which may help minimize the introduction of bacteria and foreign material into the surgical pocket.
“The purchase of Keller Medical demonstrates Allergan’s ongoing commitment to excellence in breast augmentation and reconstruction surgery,” said Louis P. Bucky, MD, Clinical Professor of Surgery, Division of Plastic Surgery at the University of Pennsylvania School of Medicine and Chief of Plastic Surgery at Pennsylvania Hospital. “The Keller Funnel has become an innovative component to deliver the highest level of care for my cosmetic and reconstructive breast implant patients.”